New concepts in sepsis

Current Opinion in Critical Care

Volumn 8, Issue 5, 2002, Pages 465-472

  Sessler, Curtis N ^a,b   Shepherd, Wes ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CORTICOSTEROID; DOBUTAMINE; DROTRECOGIN; HYDROCORTISONE; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; INOTROPIC AGENT; NORADRENALIN; VASOPRESSIN;

BLOOD CLOTTING DISORDER; CELL HYPOXIA; CLINICAL TRIAL; HUMAN; INFECTION CONTROL; INFLAMMATORY CELL; MORTALITY; PATHOPHYSIOLOGY; RESUSCITATION; REVIEW; SEPSIS;

AGE FACTORS; HUMANS; INTENSIVE CARE UNITS; SEPSIS; SHOCK, SEPTIC; UNITED STATES;

EID: 0036791112     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200210000-00016     Document Type: Review

References (70)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Alberti C, Brun-Buisson C, Burchardi H, et al.: Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med 2002, 28:108-121.
3. Hubacek JA, Stuber F, Frohlich D, et al.: Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001, 29:557-561.
4. Arnalich F, Lopez-Maderuelo D, Codoceo R, et al.: Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002, 127:331-336.
5. Lorenz E, Mira JP, Frees KL, et al.: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162:1028-1032.
6. McIntyre L, Walley KR: Importance of underlying mechanism and genotype on outcome of sepsis trials. Crit Care Med 2001, 29:677-679.
7. Dorman T, Faraday N: Do gene variants really explain the heterogeneous outcomes in sepsis? Crit Care Med 2001, 29:684-685.
8. Bouchon A, Facchetti F, Weigand MA, et al.: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.
9. Cohen J: TREM-1 in sepsis. Lancet 2001, 358:776-778.
10. Nathan C, Ding A: TREM-1: a new regulator of innate immunity in sepsis syndrome. Nat Med 2001, 7:530-532.
11. Lien E, Ingalls RR: Toll-like receptors. Crit Care Med 2002, 30(suppl):S1-S11.
12. Beutler B: Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002, 9:2-10.
13. Martinez C, Abad C, Delgado M, et al.: Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 2002, 99:1053-1058.
14. Saenz JJ, Izura JJ, Manrique A, et al.: Early prognosis in severe sepsis via analyzing the monocyte immunophenotype. Intensive Care Med 2001, 27:970-977.
15. Weighardt H, Heidecke CD, Westerholt A, et al.: Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann Surg 2002, 235:560-567.
16. Adams JM, Hauser CJ, Livingston DH, et al.: Early trauma polymorphonuclear neutrophil responses to chemokines are associated with development of sepsis, pneumonia, and organ failure. J Trauma 2001, 51:452-456.
17. Gregory SH, Cousens LP, van Rooijen N, et al.: Complementary adhesion molecules promote neutrophil-Kupffer cell interaction and the elimination of bacteria taken up by the liver. J Immunol 2002, 168:308-315.
18. Hack CE, Zeerleder S: The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001, 29(suppl):S21-S27.
19. Fujimi S, Ogura H, Tanaka H, et al.: Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma 2002, 52:443-448.
20. Ogura H, Kawasaki T, Tanaka H, et al.: Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001, 50:801-809.
21. Gao XP, Standiford TJ, Rahman A, et al.: Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by gram-negative sepsis: studies in p47(phox-/-) and gp91 (phox-/-) mice. J Immunol 2002, 168:3974-3982.
22. Leone M, Boutiere B, Camoin-Jau L, et al.: Systemic endothelial activation is greater in septic than in traumatic- hemorrhagic shock but does not correlate with endothelial activation in skin biopsies. Crit Care Med 2002, 30:808-814.
23. Green J, Doughty L, Kaplan SS, et al.: The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 2002, 87:218-223.
24. Pettila V, Pentti J, Pettila M, et al.: Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 2002, 30:271-275.
25. Yan SB, Helterbrand JD, Hartman DL, et al.: Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001, 120:915-922.
26. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595.
27. Ma P, Danner RL: The many faces of sepsis-induced vascular failure. Crit Care Med 2002, 30:947-949.
28. Takakura K, Taniguchi T, Muramatsu I, et al.: Modification of alpha1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 2002, 30:894-899.
29. Pleiner J, Heere-Ress E, Langenberger H, et al.: Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2002, 22:95-100.
30. Piepot HA, Groeneveld AB, van Lambalgen AA, et al.: The role of inducible nitric oxide synthase in lipopolysaccharide-mediated hyporeactivity to vasoconstrictors differs among isolated rat arteries. Clin Sci (Lond) 2002, 102:297-305.
31. Bucher M, Hobbhahn J, Taeger K, et al.: Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002, 282:R979-R984.
32. Zaloga GP: Sepsis-induced adrenal deficiency syndrome. Crit Care Med 2001, 29:688-690.
33. Loisa P, Rinne T, Kaukinen S: Adrenocortical function and multiple organ failure in severe sepsis. Acta Anesthesiol Scand 2002, 46:145-151.
34. Schroeder S, Wichers M, Klingmuller D, et al.: The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001, 29:310-316.
35. Ammann P, Fehr T, Minder El, et al.: Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001, 27:965-969.
36. Wu AH: Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? Intensive Care Med 2001, 27:959-961.
37. Beranek JT: Cardiomyocyte apoptosis contributes to the pathology of the septic shock heart. Intensive Care Med 2002, 28:218.
38. Knuefermann P, Nemoto S, Baumgarten G, et al.: Cardiac inflammation and innate immunity in septic shock: is there a role for toll-like receptors? Chest 2002, 121:1329-1336.
39. Sair M, Etherington PJ, Peter Winlove C, et al.: Tissue oxygenation and perfusion in patients with systemic sepsis. Crit Care Med 2001, 29:1343-1349.
40. Sakka SG, Reinhart K, Wegscheider K, et al.: Variability of splanchnic blood flow in patients with sepsis. Intensive Care Med 2001, 27:1281-1287.
41. Creery D, Fraser DD: Tissue dysoxia in sepsis: getting to know the mitochondrion. Crit Care Med 2002, 30:483-484.
42. Fink MP: Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin 2001, 17:219-237.
43. Jimenez MF, Marshall JC: Source control in the management of sepsis. Intensive Care Med 2001, 27(suppl 1):S49-S62.
44. Fish DN: Optimal antimicrobial therapy for sepsis. Am J Health Syst Pharm 2002, 59(suppl 1):S13-S19.
45. Bochud PY, Glauser MP, Calandra T: Antibiotics in sepsis. Intensive Care Med 2001, 27(suppl 1):S33-S48.
46. Rivers E, Nguyen B, Havstad S, et al.: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
47. Vincent JL: Hemodynamic support in septic shock. Intensive Care Med 2001, 27(suppl 1):S80-S92.
48. Vincent JL, Sunday Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34:1084-1093.
49. Duranteau J, Sitbon P, Teboul JL, et al.: Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 1999, 27:893-900.
50. Lebuffe G, Levy B, Neviere R, et al.: Dobutamine and gastric-to-arterial carbon dioxide gap in severe sepsis without shock. Intensive Care Med 2002, 28:265-271.
51. Tsuneyoshi I, Yamada H, Kakihana Y, et al.: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001, 29:487-493.
52. Patel BM, Chittock DR, Russell JA, et al.: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96:576-582.
53. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 2002, 359:1209-1210.
54. Martin GS, Bernard GR: Airway and lung in sepsis. Intensive Care Med 2001, 27(suppl 1):S63-S79.
55. Ebihara S, Hussain SN, Danialou G, et al.: Mechanical ventilation protects against diaphragm injury in sepsis: interaction of oxidative and mechanical stresses. Am J Respir Crit Care Med 2002, 165:221-228.
56. Schetz M: Vasopressors and the kidney. Blood Purif 2002, 20:243-251.
57. Briegel J, Forst H, Haller M, et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999, 27:723-732.
58. Bollaert PE, Charpentier C, Levy B, et al.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26:645-650.
59. Briegel J, Jochum M, Gippner-Steppert C, et al.: Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001, 12(suppl 17):S70-S74.
60. van Leeuwen HJ, van der Bruggen T, van Asbeck BS, et al.: Effect of corticosteroids on nuclear factor-kappaB activation and hemodynamics in late septic shock. Crit Care Med 2001, 29:1074-1077.
61. Alejandria MM, Lansang MA, Dans LF, et al.: Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2001, 2:CD001090.
62. Cole L, Bellomo R, Hart G, et al.: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002, 30:100-106.
63. Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
64. Bernard GR, Ely EW, Wright TJ, et al.: Safety and dose relation of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29:2051-2059.
65. Graf J, Doig GS, Cook DJ, et al.: Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med 2002, 30:461-472.
66. Warren BL, Eid A, Singer P, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
67. Abraham E, Laterre PF, Garbino J, et al.: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001, 29:503-510.
68. Reinhart K, Menges T, Gardlund B, et al.: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyper-inflammatory response during severe sepsis: the RAMSES study. Crit Care Med 2001, 29:765-769.
69. Abraham E, Reinhart K, Svoboda P, et al.: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multi-center, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001, 29:2081-2089.
70. de Jonge E, Dekkers PE, Creasey AA, et al.: Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001, 183:1815-1818.